Astellas Pharma: Pipeline, Products, Performance, Potential

Date: January 22, 2010
Pages: 146
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AAA86A7FFE4EN
Leaflet:

Download PDF Leaflet

Astellas Pharma: Pipeline, Products, Performance, Potential
On 1st April 2005, Yamanouchi Pharmaceutical Co Ltd and Fujisawa Pharmaceutical Co Ltd merged. Yamanouchi, the surviving company, was renamed Astellas, and Fujisawa was dissolved (merger ratio = Yamanouchi: Fujisawa 1:0.71). Headquarters for the combined business are in Tokyo, Japan, with locally operated Regional Headquarters in the US, Europe and Asia.

The aim of Astellas is to secure a top share in the Japanese pharmaceutical market; the combined company now has 5,000 medical representatives, the largest among domestic pharmaceutical companies, and it aims to develop an even stronger sales and marketing infrastructure. The company also expects to be able to provide broad coverage for both primary care physicians and speciality markets in the US by leveraging the existing infrastructures to accelerate expansion of the US business.

The combined company is aiming to achieve economies of scale through the integration of the R&D, and sales and marketing capabilities of both the companies, as well as to further improve its profitability through the establishment of more efficient operational structures.

Astellas has a broad portfolio, with strength in the areas of Cardiovascular, Inflammation/Immunology, Urology, Gastrointestinal, Central Nervous System and Infectious Disease.
EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting
Cardiovascular
  Adenoscan (adenosine)
  Lexiscan (regadenoson)
  Lipitor (atorvastatin)
  Micardis (telmisartan)
Inflammation & Immunology
  Celecox (celecoxib)
  Prograf (tacrolimus)
Urology
  Harnal/Omnic/Flomax (tamsulosin)
  Vesicare (solifenacin)
Infectious Disease
  Funguard/Mycamine (micafungin)
  Geninax (garenoxacin)
Gastrointestinal
  Gaster/Pepcid (famotidine)
Central Nervous System
  Myslee (zolpidem)
  Seroquel (quetiapine)
Dermatology
  Protopic (tacrolimus)
Oncology
  Eligard (leuprolide)

OPERATIONAL DATA

A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
Skip to top


Eisai: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 118 pages
Takeda Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 124 pages
Allergan: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2009 · 80 pages

Ask Your Question

Astellas Pharma: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: